UNSPSC 41105503: Electroelution systems

UNSPSC 41105503 Electroelution systems (Commodity) covers DNA extraction and amplification reagents, consumables, and related laboratory supplies used by state and local forensic laboratories, public health agencies, and research facilities for human identification, newborn screening, and pathogen detection work. State and local governments under this code procure specialized DNA extraction reagents (such as Qiagen EZ1 and Extracta DBS products), STR amplification kits (PowerPlex Fusion, RapidHIT consumables, and 5-Dye multiplex kits), control cartridges, qPCR master mixes, capillaries, and associated consumables required for forensic DNA casework, CODIS indexing, newborn screening for genetic disorders, and carbapenem-resistant pathogen detection. Recent solicitations also include requests for digital PCR instruments with integrated DNA extractors and automated liquid handling systems, suggesting the code captures both standalone reagents and the equipment platforms that deploy them in high-throughput settings.

State crime laboratories and public health agencies dominate recent activity. The Texas Department of Public Safety Crime Lab and Texas Health and Human Services Commission have posted multiple IFBs and RFPs since February 2026; the Mississippi Forensic Laboratory, Illinois State Police, and City of Palm Bay, Florida have also solicited under this code. The geographic concentration is heaviest in Texas (five of nine recent opportunities) with secondary activity in Mississippi, Illinois, and Florida. Representative recent procurements include the Texas Department of Public Safety's IFB 405-26R0017287 for RapidHIT DNA consumables (9 line items, bids due July 22, 2026), the Texas Health and Human Services Commission's IFB HHS0017640 for QuantaBio DNA extraction reagents supporting newborn screening (bids due July 15, 2026, historical spend $2.5 million for a three-month period), and the Illinois State Police's nine-year IFB B-51025 for Promega PowerPlex STR amplification kits across nine state laboratory locations (bids due February 20, 2026). Several solicitations are restricted to proprietary products (Qiagen, Promega, Life Technologies, QIAGEN) or sole-source awards, limiting competition to authorized dealers.